Vitamin B12 conjugation of peptide-YY3-36 decreases food intake compared to native peptide-YY3-36 upon subcutaneous administration in male rats

Endocrinology

Volumn 156, Issue 5, 2015, Pages 1739-1749

  Henry, Kelly E ^a   Elfers, Clinton T ^b   Burke, Rachael M ^a   Chepurny, Oleg G ^c   Holz, George G ^c   Blevins, James E ^d,e   Roth, Christian L ^b,e   Doyle, Robert P ^a,c  

^a SYRACUSE UNIVERSITY   (United States)

^b SEATTLE CHILDREN S RESEARCH INSTITUTE   (United States)

^c STATE UNIVERSITY OF NEW YORK   (United States)

^d VA PUGET SOUND HEALTH CARE SYSTEM   (United States)

^e UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYANOCOBALAMIN; NEUROPEPTIDE Y1 RECEPTOR; NEUROPEPTIDE Y2 RECEPTOR; PEPTIDE YY [3-36]; PROTEIN FOS; DRUG CARRIER; NEUROPEPTIDE Y RECEPTOR; PEPTIDE FRAGMENT; PEPTIDE YY; VITAMIN B COMPLEX;

ADULT; ANIMAL CELL; ANIMAL EXPERIMENT; AREA UNDER THE CURVE; ARTICLE; CALCIUM MOBILIZATION ASSAY; CARBOXY TERMINAL SEQUENCE; CLICK CHEMISTRY; CONTROLLED STUDY; DRUG ABSORPTION; DRUG CONJUGATION; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG HALF LIFE; DRUG STRUCTURE; FOOD INTAKE; MALE; MAXIMUM PLASMA CONCENTRATION; MOLECULAR DYNAMICS; NONHUMAN; PHARMACODYNAMICS; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; VOLUME OF DISTRIBUTION; WEIGHT GAIN; YOUNG ADULT; AGONISTS; ANIMAL; DRUG EFFECTS; EATING; METABOLISM; PHYSIOLOGY; SPRAGUE DAWLEY RAT; SUBCUTANEOUS DRUG ADMINISTRATION;

ANIMALS; DRUG CARRIERS; EATING; INFUSIONS, SUBCUTANEOUS; MALE; PEPTIDE FRAGMENTS; PEPTIDE YY; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, NEUROPEPTIDE Y; VITAMIN B 12; VITAMIN B COMPLEX;

EID: 84929012827     PISSN: 00137227     EISSN: 19457170     Source Type: Journal    
DOI: 10.1210/en.2014-1825     Document Type: Article

References (46)

1. Karra E, Batterham RL. The role of gut hormones in the regulation of body weight and energy homeostasis. Mol Cell Endocrinol. 2010; 316(2):120-128.
2. Batterham RL, Cowley MA, Small CJ, et al. Gut hormone PYY3-36 physiologically inhibits food intake. Nature 2002;418(6898):650-654.
3. Broom DR, Batterham RL, King JA, Stensel DJ. Influence of resistance and aerobic exercise on hunger, circulating levels of acylated ghrelin, and peptide YY in healthy males.AmJ Physiol Regul Integr Comp Physiol. 2009;296(1):R29-R35.
4. Koda S, Date Y, Murakami N, et al. The role of the vagal nerve in peripheral PYY3-36-induced feeding reduction in rats. Endocrinology. 2005;146(5):2369-2375.
5. Blevins JE, Chelikani PK, Haver AC, Reidelberger RD. PYY(3-36) induces Fos in the arcuate nucleus and in both catecholaminergic and non-catecholaminergic neurons in the nucleus tractus solitarius of rats. Peptides. 2008;29(1):112-119.
6. Halatchev IG, Ellacott KL, Fan W, Cone RD. Peptide YY3-36 inhibits food intake in mice through a melanocortin-4 receptor-independent mechanism. Endocrinology. 2004;145(6):2585-2590.
7. Neary NM, Small CJ, Druce MR, et al. Peptide YY3-36 and glucagon- like peptide-17-36 inhibit food intake additively. Endocrinology. 2005;146(12):5120-5127.
8. Moran TH, Smedh U, Kinzig KP, Scott KA, Knipp S, Ladenheim EE. Peptide YY(3-36) inhibits gastric emptying and produces acute reductions in food intake in rhesus monkeys. Am J Physiol Regul Integr Comp Physiol. 2005;288(2):R384-R388.
9. Koegler FH, Enriori PJ, Billes SK, et al. Peptide YY(3-36) inhibits morning, but not evening, food intake and increases body weight in rhesus macques. Diabetes 2005;54(11):3198-3204.
10. Helou N, Obeid O, Azar ST, Hwalla N. Variation of postprandial PYY 3-36 response following ingestion of differing macronutrient meals in obese females. Ann Nutr Metab. 2008;52(3):188-195.
11. Batterham RL, CowleyMA, Ellis SM, et al. Inhibition of food intake in obese subjects by peptide YY3-36. N Engl J Med. 2003;349(10): 941-948.
12. Abbott CR, Monteiro M, Small CJ, et al. The inhibitory effects of peripheral administration of peptide YY(3-36) and glucagon-like peptide-1 on food intake are attenuated by ablation of the vagalbrainstem- hypothalamic Pathway. Brain Res. 2005;1044(1):127-131.
13. Chelikani PK, Haver AC, Reidelberger RD. Comparison of the inhibitory effects of PYY(3-36) and PYY(1-36) on gastric emptying in rats. Am J Physiol Regul Integr Comp Physiol. 2004;287(5): R1064-R1070.
14. le RouxCW, Batterham RL, Aylwin SJ, et al. Attenuated peptideYY release in obese subjects is associated with reduced satiety. Endocrinology. 2006;147(1):3-8.
15. Roth CL, Bongiovanni KD, Gohlke B, Woelfle J. Changes in dynamic insulin and gastrointestinal hormone secretion in obese children. J Pediatr Endocrinol Metab. 2010;23(12):1299-1309.
16. Roth CL, Enriori PJ, Harz K, Woelfle J, Cowley MA, Reinehr T. Peptide YY is a regulator of energy homeostasis in obese children before and after weight loss. J Clin Endocrinol Metab. 2005;90(12): 6386-6391.
17. Addison ML, Minnion JS, Shillito JC, et al. A role for metalloendopeptidases in the breakdown of the gut hormone, PYY 3-36. Endocrinology. 2011;152(12):4630-4640.
18. Gantz I, Erondu N, MallickM, et al. Efficacy and safety of intranasal peptide YY3-36 for weight reduction in obese adults. J Clin Endocrinol Metab. 2007;92(5):1754-1757.
19. Halatchev IG, Cone RD. Peripheral administration of PYY(3-36) produces conditioned taste aversion in mice. Cell Metab. 2005;1(3): 159-168.
20. Degen L, Oesch S, Casanova M, et al. Effect of peptide YY3-36 on food intake in humans. Gastroenterology. 2005;129(5):1430-1436.
21. Shechter Y, Tsubery H, Mironchik M, Rubinstein M, Fridkin M. Reversible PEGylation of peptide YY3-36 prolongs its inhibition of food intake in mice. FEBS Lett. 2005;579(11):2439-2444.
22. Ehrlich GK, Michel H, Truitt T, et al. Preparation and characterization of albumin conjugates of a truncated peptide YY analogue for half-life extension. Bioconjug Chem. 2013;24(12):2015-2024.
23. Baraboi ED, Michel C, Smith P, Thibaudeau K, Ferguson AV, Richard D. Effects of albumin-conjugated PYY on food intake: the respective roles of the circumventricular organs and vagus nerve. Eur J Neurosci. 2010;32(5):826-839.
24. Nielsen MJ, Rasmussen MR, Andersen CB, Nexo E, Moestrup SK. Vitamin B12 transport from food to the body's cells-a sophisticated, multistep pathway. Nat Rev Gastroenterol, Hepatol. 2012; 9(6):345-354.
25. Russell-Jones GJ, Westwood S, Farnworth PG, Findlay JK, Burger HG. Synthesis of LHRH antagonists suitable for oral administration via the vitamin B12 uptake system. Bioconjug Chem. 1995;6(1)34-42.
26. Russell-Jones GJ, Westwood S, Habberfield AD. Vitamin B12 mediated oral delivery systems for granulocyte-colony stimulating factor and erythropoietin. Bioconjug Chem. 1995;6(1):459-465.
27. Petrus AK, Vortherms AR, Fairchild TJ, Doyle RP. Vitamin B12 as a carrier for the oral delivery of insulin. ChemMedChem. 2007; 2(12):1717-1721.
28. Fazen CH, Valentin D, Fairchild TJ, Doyle RP. Oral delivery of the appetite suppressing peptide hPYY(3-36) through the vitamin B12 uptake pathway. J Med Chem. 2011;54(24):8707-8711.
29. Clardy-James S, Chepurny OG, Leech CA, Holz GG, Doyle RP. Synthesis, characterization and pharmacodynamics of vitamin- B(12)-conjugated glucagon-like peptide-1. ChemMedChem. 2013; 8(4):582-586.
30. Nonaka N, Shioda S, Niehoff ML, Banks WA. Characterization of blood-brain barrier permeability to PYY3-36 in the mouse. J Pharmacol Exp Ther. 2003;306(3):948-953.
31. Lazar GS, Carmel R. Cobalamin binding and uptake in vitro in the human central nervous system. J Lab Clin Med. 1981;97(1):123-133.
32. Kostenis E, Martini L, Ellis J, et al.Ahighly conserved glycine within linker I and the extreme C terminus of G protein α subunits interact cooperatively in switching G protein-coupled receptor-to-effector specificity. J Pharmacol Exp Ther. 2005;313(1):78-87.
33. Pedersen SL, Holst B, Vrang N, Jensen KJ. Modifying the conserved C-terminal tyrosine of the peptide hormone PYY3-36 to improve Y2 receptor selectivity. J Pept Sci. 2009;15(11):753-759.
34. Kolb HC, Finn MG, Sharpless, KB. Click chemistry: diverse chemical function from a few good reactions. Angew Chem Int Ed. 2001; 40(11):2004-2021.
35. Vrang N, Madsen AN, Tang-Christensen M, Hansen G, Larsen PJ. PYY(3-36) reduces food intake and body weight and improves insulin sensitivity in rodent models of diet-induced obesity. Am J Physiol Regul Integr Comp Physiol. 2006;291(2):R367-R375.
36. Chelikani PK, Haver AC, Reeve JR, Keire DA, Reidelberger RD. Daily, intermittent intravenous infusion of peptide YY(3-36) reduces daily food intake and adiposity in rats. Am J Physiol Regul Integr Comp Physiol. 2006;290(2):R298-R305.
37. Pittner RA, Moore CX, Bhavsar SP, et al. Effects of PYY[3-36] in rodent models of diabetes and obesity. In J Obes Relat Metab Disord. 2004;28(8):963-971.
38. Chen DY, Deutsch JA, Gonzalez MF, Gu Y. The induction and suppression of c-fos expression in the rat brain by cholecystokinin and its antagonist L364, 718. Neurosci Lett. 1993;149(1):91-94.
39. Day HE, McKnight AT, Poat JA, Hughes J. Evidence that cholecystokinin induces immediate early gene expression in the brainstem, hypothalamus and amygdala of the rat by a CCKA receptor mechanism. Neuropharmacology. 1994;33(6):719-727.
40. Fraser KA, Raizada E, Davison JS. Oral-pharyngeal-esophageal and gastric cues contribute to meal-induced c-fos expression. Am J Physiol. 1995;268(1 Pt 2):R223-R230.
41. Parker RM, Herzog H. Regional distribution of Y-receptor subtype mRNAs in rat brain. Eur J Neurosci. 1999;11(4):1431-1448.
42. Mahaut S, Dumont Y, Fournier A, Quirion R, Moyse E. Neuropeptide Y receptor subtypes in the dorsal vagal complex under acute feeding adaptation in the adult rat. Neuropeptides. 2010; 44(2):77-86.
43. Shapiro RE, Miselis RR. The central organization of the vagus nerve innervating the stomach of the rat. J Comp Neurol. 1985;238(4): 473-488.
44. Kalia M, Mesulam MM. Brain stem projections of sensory and motor components of the vagus complex in the cat: I. The cervical vagus and nodose ganglion. J Comp Neurol. 1980;193(2):435-465.
45. Chelikani PK, Haver AC, Reidelberger RD. Intermittent intraperitoneal infusion of peptide YY(3-36) reduces daily food intake and adiposity in obese rats. Am J Physiol Regul Integr Comp Physiol. 2007;293(1):R39-R46.
46. Reidelberger RD, Haver AC, Chelikani PK, Buescher JL. Effects of different intermittent peptide YY (3-36) dosing strategies on food intake, body weight, and adiposity in diet-induced obese rats. Am J Physiol Regul Integr Comp Physiol. 2008;295(2):R449-R458.